Beta-thalassemia major. Beta thalassemia
Conditions
Interventions
Intervention 1: Participants in the intervention group receive 500 mg of resveratrol daily for 6 weeks. Intervention 2: Participants in the control group receive routine treatment to allow comparison
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
10 Years to 40 Years
Inclusion criteria
Inclusion criteria: Patients with beta-thalassemia major referred to Baqaei 2 hospital Aged between 10 and 40 years, who have provided written informed consent to participate in the study
Exclusion criteria
Exclusion criteria: Use of medications affecting inflammation or iron metabolism that cannot be controlled Presence of severe underlying diseases (such as advanced heart or liver failure) Hypersensitivity to resveratrol or related substances
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in inflammatory markers in patients with beta-thalassemia major. Timepoint: Sample collection and measurement at baseline (before the intervention) and after 6 weeks. Method of measurement: Measurement of inflammatory markers using standard laboratory methods including erythrocyte sedimentation rate and C-reactive protein.;Changes in iron-overload markers in patients with beta-thalassemia major. Timepoint: Sample collection and measurement at baseline (before the intervention) and after 6 weeks. Method of measurement: Measurement of iron-overload markers using standard laboratory methods including serum ferritin and transferrin saturation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Reza Mahmoudian-Sani
Ahvaz University of Medical Sciences
Outcome results
None listed